1P-LSD 150MCG
$500
1P-LSD 150MCG first appeared on the online research chemical market in January 2015. Although it was likely discovered in an academic setting, it is unknown who first synthesized 1P-LSD,
Description
1P-Lsd 150MCG – 1P-Lsd for sale. 1P-LSD or 1-propionyl-lysergic acid diethylamide is a psychedelic drug of the lysergamide class that is a derivative and functional analogue of LSD and a homologue of ALD-52. It has been sold online as a designer drug since 2015. It modifies the LSD molecule by adding a propionyl group to the nitrogen molecule of LSD’s indol
1P-LSD 150MCG, short for 1 Propionyl Lysergic Acid Diethylamide is the hallucinogenic ,psychedelic drug that belongs to the family of lysergamide. This substance has almost no history of human use. This substance has never been reported in any formal scientific literature making it unknown to the public and the academics. 1p-LSD blotters for sale online. 1P-LSD (1-propionyl-lysergic acid diethylamide) is a novel psychedelic of the lysergamide class. 1P-LSD is from the same family as ALD-52 and LSD. The results of 1P-LSD are believed to include cognitive euphoria, distorted perception of colors, time, sounds and shapes, hallucinations, and other results similar to those of standard LSD.
1P-LSD 150MCG has been sold online as a research chemical (also called “designer drug”) since 2015, but the original synthesis date of 1P-LSD is unknown. Unlike most research chemicals, it has no documented record in the research literature before its emergence on the online research chemical market in 2015.[1]
It was marketed as a legal alternative to LSD alongside other novel lysergamides like ALD-52, ETH-LAD, and AL-LAD. In 2019, it became part of a group of molecules studied by the French laboratory Caulredaitens. Subjective effects include geometric visual hallucinations, time distortion, enhanced introspection, conceptual thinking, euphoria, and ego loss. User reports indicate that the subjective effects of 1P-LSD are extremely similar to those of LSD. It is theorized to act as a prodrug for LSD.
This hypothesis is supported by the results of a study that demonstrated 1P-LSD is metabolized to LSD in rats. This predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. Its classical psychedelic effects and favorable tolerability has led it to become popular among novel substance users who use it interchangeably with LSD.
Very little data exists about the pharmacological properties, metabolism, and toxicity of 1P-LSD. It is presumed to have a similar toxicity and risk profile as LSD, although there are no formal studies that prove this. It is highly advised to use harm reduction practices if using this substance.
1P-LSD 150MCG first appeared on the online research chemical market in January 2015. Although it was likely discovered in an academic setting, it is unknown who first synthesized 1P-LSD, as the substance does not appear in any academic literature pre-dating its arrival on the research chemical market.
1P-LSD 150MCG .Interestingly, the future usage of 1-alkylated lysergamide derivatives as a means to bypass controlled substance laws banning LSD as a precursor was foreseen in a DEA report from 1988:
| “ | …a reduction in hallucinogenic activity may become acceptable to the U.S. clandestine chemist when he notes that lysergic acid amide is listed as a Schedule III substance in the CFR; therefore, structurally similar substances of this compound are exempted from the CsA amendment.A lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment. |
Reviews
There are no reviews yet.